Last Update 24 Jun 26
Fair value Decreased 0.033%LONN: Bioprocessing Recovery And ADC Licensing Pipeline Will Drive Future Upside
Analysts have trimmed their average price target for Lonza Group to roughly CHF 663 from about CHF 664, reflecting slightly higher discount rate assumptions and updated expectations for revenue growth, profit margins, and future P/E multiples in light of recent research that includes reduced targets of CHF 590 and CHF 656 from major banks.
Analyst Commentary
Recent research on Lonza Group shows that analysts are adjusting their models and price targets while still weighing the company against broader views on life science tools, bioprocessing and quality assurance demand. These changes give you a window into how the market is thinking about Lonza's execution risk, growth profile and valuation support.
Bullish Takeaways
- Bullish analysts continue to see upside in Lonza Group despite trimmed price targets, which suggests they still view the current valuation as supported by the company’s role in life science tools and services.
- Comments about "green shoots of recovery" in bioprocessing and quality assurance point to improving sentiment toward the end markets that matter for Lonza's growth pipeline and capacity utilization.
- The retention of Buy ratings alongside lower targets indicates confidence that Lonza can execute on its project backlog and contract portfolio, even with updated risk assumptions.
- Adjustments framed around risk-adjusted return expectations imply that bullish analysts are fine-tuning discount rates and multiples rather than abandoning their longer-term investment case in Lonza Group.
Bearish Takeaways
- Analysts setting lower price targets, such as CHF 590 and CHF 656, reflect caution that prior expectations for Lonza's revenue growth, margins or P/E may have been too optimistic.
- Comments that market expectations for life science tools "remain bearish" highlight concern that sector sentiment and capital allocation are currently skewed toward other healthcare segments, which can weigh on Lonza's valuation.
- The focus on higher discount rate assumptions signals that some analysts see elevated risk around execution and project timing, which feeds through into more conservative pricing of Lonza Group shares.
- With preferred ideas in the tools sector identified elsewhere, there is an implied opportunity cost for investors, as some bearish analysts appear to see stronger risk and reward profiles outside Lonza despite still acknowledging its quality positioning.
What's in the News for Lonza Group
- Lonza Group issued an exclusive license to Antharis Therapeutics to advance next-generation dual payload antibody drug conjugates targeting gastrointestinal cancers, using Lonza's synthesis and CDMO capabilities in oncology. Source: Antharis Therapeutics collaboration announcement.
- Lonza Group and Antharis Therapeutics entered a target-specific licensing agreement that gives Antharis rights to Lonza's dual payload ADC technology platform for multicancer applications, with Lonza eligible for upfront, milestone and royalty payments while supplying payload and linker components. Source: Client announcement.
- Stipple Bio signed a multi-target licensing agreement with Lonza Group for access to Lonza's ADC technology platform, including GlycoConnect, HydraSpace and toxSYN technologies, with Lonza set to receive upfront, clinical, regulatory and commercial milestones plus royalties, while supplying proprietary technology components. Source: Client announcement.
- Iconovo and Lonza Group signed a collaboration agreement around spray-dried formulation capabilities for inhaled biologics, vaccines and large molecules, setting out terms for priority services and an umbrella framework for future project-specific deals tied to inhaler platforms such as ICOres, ICOpre, ICOcap, ICOone and ICOone nasal. Source: Strategic collaboration announcement.
- Lonza Group is working with Simulations Plus and the U.S. Food and Drug Administration on a funded research collaboration to create a mechanistic framework for predicting in vivo performance of amorphous solid dispersion drug products, combining advanced dissolution testing, physiologically based modeling and AI-enabled workflows to support model-informed drug development and potential reductions in certain clinical bioequivalence studies. Source: Product-related collaboration announcement.
Valuation Changes for Lonza Group
- Fair Value: The average fair value estimate for Lonza Group is now CHF 663.30, slightly lower than the prior CHF 663.52. This reflects a very small adjustment in analyst models.
- Discount Rate: The discount rate assumption has risen slightly from 4.85% to 4.94%. This points to a modest increase in perceived risk or required return.
- Revenue Growth: The assumed long term revenue growth rate is now 11.11%, compared with 11.08% previously. This indicates a marginally higher growth assumption for CHF revenue.
- Net Profit Margin: The projected net profit margin has edged down slightly from 18.86% to 18.85%. This suggests a very small reduction in expected profitability on CHF earnings.
- Future P/E: The future P/E multiple used in the models has moved slightly higher, from 31.26x to 31.32x. This implies a modestly higher valuation multiple for Lonza Group on expected earnings.
1 viewusers have viewed this narrative update
Key Takeaways
- Sustained demand and investment in advanced manufacturing are driving stable, higher-margin growth and improved operational efficiency.
- Divesting non-core segments and expanding globally enhance strategic focus, revenue resilience, and long-term capital allocation efficiency.
- Heavy reliance on unstable business segments, high expansion risks, adverse currency trends, rising competition, and divestment pressures threaten profitability, growth, and financial flexibility.
Catalysts
About Lonza Group- Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
- Robust and sustained demand for Lonza's biologics and advanced therapy manufacturing capacity, driven by the global increase in chronic and complex diseases (notably oncology, autoimmune disorders, and new modalities like cell and gene therapies), is fueling long-term revenue growth with strong order visibility (as seen in high utilization rates and multi-year contracts), supporting top-line expansion and earnings stability.
- Lonza's strategic and diversified investments in cutting-edge manufacturing facilities (notably in mammalian, bioconjugate, cell & gene, and highly potent APIs) and automation upgrades (including the ongoing Vacaville and Visp expansions) are set to capture growing customer demand for next-generation therapies and support operating leverage, pointing to higher-margin growth and improved group EBITDA margins.
- Global pharma's ongoing shift toward outsourcing more complex manufacturing to specialized CDMOs, in tandem with increased biopharma R&D budgets, is sustaining high contract-wins, repeat business, and a diverse customer mix for Lonza, which underpins recurring revenue streams and reduces volatility in cash flow and earnings.
- Geographical expansion (notably in the U.S., APAC, and Europe) and Lonza's strong networked global footprint offer increased resilience-minimizing risk from localized supply chain disruptions or tariffs-while helping to drive continued customer acquisition and revenue growth from multiple major markets, supporting long-term earnings.
- The planned divestment of Capsules and Health Ingredients (CHI), a lower-growth, albeit cash-generative, segment, will free up capital for higher-return investments in core CDMO operations and potentially lift return on invested capital and free cash flow over the medium term, positively impacting future margins and capital allocation efficiency.
Lonza Group Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Lonza Group's revenue will grow by 11.1% annually over the next 3 years.
- Analysts assume that profit margins will increase from 13.9% today to 18.8% in 3 years time.
- Analysts expect earnings to reach CHF 1.7 billion (and earnings per share of CHF 24.22) by about June 2029, up from CHF 909.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting CHF2.0 billion in earnings, and the most bearish expecting CHF1.5 billion.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 31.4x on those 2029 earnings, down from 39.6x today. This future PE is lower than the current PE for the GB Life Sciences industry at 36.8x.
- Analysts expect the number of shares outstanding to decline by 0.32% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 4.94%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- The Specialized Modalities business faces notable volatility due to reliance on a small pipeline of commercial Cell & Gene Therapy (CGT) products, leading to uneven asset utilization and sensitivity to clinical setbacks; this creates significant risk to both revenue stability and margins in that segment.
- Expansion and ramp-up of major facilities (such as Vacaville and Visp) involve high CapEx intensity and operational execution risk; delays, underutilization, or cost overruns during this expansion period could lead to higher depreciation charges and reduced return on invested capital, negatively impacting future earnings and free cash flow.
- Currency fluctuations, especially a strong Swiss franc against the US dollar, have created noticeable headwinds (−2.5% to −3.5% expected impact on sales and EBITDA for 2025), potentially reducing reported revenue and profit margins if the trend persists or intensifies.
- Increasing competition and customer negotiations in the US CDMO market could pressure pricing and limit Lonza's ability to maintain margin expansion, particularly as new customer contracts are required to offset expiring legacy contracts (e.g., Roche at Vacaville); difficulties in signing sufficient large contracts may impair revenue growth and backlog.
- The eventual divestment of Capsules and Health Ingredients (CHI), which is more cash-generative than the core CDMO business, may reduce the group's near-term free cash flow, while the CDMO business is still transitioning to a less CapEx-intensive, more cash-generative profile-posing a temporary risk to group-wide liquidity and financial flexibility.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of CHF663.3 for Lonza Group based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CHF815.0, and the most bearish reporting a price target of just CHF550.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CHF9.0 billion, earnings will come to CHF1.7 billion, and it would be trading on a PE ratio of 31.4x, assuming you use a discount rate of 4.9%.
- Given the current share price of CHF515.2, the analyst price target of CHF663.3 is 22.3% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Lonza Group?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
There are no other narratives for this company.
View all narratives